Volume 27, the first thematic volume in the Series, provides an overview of present knowledge with regard to the pharmacological and clinical aspects of antidiabetic drugs. It aims to stimulate further consideration of possible concepts in the development of new antidiabetic drugs.

Volume 27, the first thematic volume in the Series, provides an overview of present knowledge with regard to the pharmacological and clinical aspects of antidiabetic drugs. It aims to stimulate further consideration of possible concepts in the development of new antidiabetic drugs.

Products of gene modification have vast implications. Creating public awareness and disseminating information on the subject seeks to demystify some of the widely held falsehoods regarding genetically modified products. This an informative, thorough and easy-to-understand guide book that aims to enlighten and debunk some of the commonly held misconceptions on products of gene modification and to give the reader a better understanding of the role genetic modification will play. The review sheds light on the safety, and application of these products in medicine, the food industry and other areas, especially those where genetic modification may represent a cheap, faster, credible and viable alternative in achieving sustainable development amongst resource-poor communities.

A history of diabetology told by renowned contributors, many have themselves already become a part of diabetes history. A must-have for every diabetologist! Diabetologists, diabetes educators, and many interested readers will appreciate this book. What is more, countless celebrations are planned for the 100th anniversary of the discovery of insulin: this book provides numerous illustrations, accounts of personal experiences, and critical remarks on the history of diabetology – in addition to the history of insulin. It spans an arc from antiquity to the work of Claude Bernard, Paul Langerhans, Josef von Mering, Apollinaire Bouchardat, Oskar Minkowski, E.P. Joslin, and F.M. Allen. The history of insulin is presented from the perspective of diabetologists from Scotland, Spain, Germany, and Poland. The history of oral antidiabetics is told by Harald Lebovitz, and the chapter about glitazones by Edwin Gale reads like a spy novel! Pierre Lefèbvre describes the work of the diabetologist Jean Pirart and the history of glucagon. Sir George Alberti has provided a chapter about the therapy of ketoacidosis, to which he himself made groundbreaking contributions. Nephropathy is presented by Hans-Henrik Parving, and Eva Kohner, Ronald Klein and Barbara E.K. Klein have contributed a chapter on retinopathy. Other contemporary topics such diabetes in pregnancy, diabetes technology, psychosocial aspects of diabetes, and the history of the EASD and ADA are also included in this book.

Intended for diabetes researchers and medical professionals who work closely with patients with diabetes, this newly updated and expanded edition provides new perspectives and direct insight into the causes and consequences of this serious medical condition from one of the foremost experts in the field. Using the latest scientific and medical developments and trends, readers will learn how to identify, prevent, and treat this challenging phenomenon within the parameters of the diabetes care regimen.

This volume continues the trend for Advances in Drug Research of shorter, but more frequent volumes. In line with the tradition of the series, chapters on general themes are interspersed with chapters on specific drug classes and targets. It will be the last volume edited by Bernard Testa and Urs A. Meyer.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.